

Medichem receives €16.2 million in funding for the FDF4EU project, granted by CDTI under the IPCEI Med4Cure framework

Barcelona, July 9th, 2025. The Centre for the Development of Industrial Technology (CDTI), under the Spanish Ministry of Science, Innovation and Universities, published the Final Resolution for the call for proposals aimed at direct and associated participants in the **Important Project of Common European Interest (IPCEI) Med4Cure**.

As outlined in the resolution, **MEDICHEM** has been awarded a grant of €16,213,766.03 as an Associated Partner of the IPCEI Med4Cure, to support the development of the FDF4EU project. This initiative aims to advance a portfolio of innovative, sustainable, and high value-added generic medicines, particularly focused on the treatment of cancer and rare diseases, to address unmet clinical needs across Europe.

The FDF4EU project will contribute to strengthening the strategic autonomy of the European pharmaceutical sector, improving patient access to effective, high-quality, and sustainably manufactured treatments. Medichem will collaborate closely with other European entities, leveraging its expertise in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The total budget of the project amounts to €35,925,343, of which €16.2 million is publicly funded through national support.

The IPCEI Med4Cure, approved by the European Commission on 28 May 2024, is the first Important Project of Common European Interest in the health sector. It brings together six EU Member States: Belgium, France, Hungary, Italy, Slovakia, and Spain, and supports 14 highly innovative scientific projects. These are led by 13 companies as direct participants and supported by 11 associated partners across four Member States.

Launched in the wake of the COVID-19 pandemic, this initiative is aligned with the goals of the European Health Union, aiming to strengthen the continent's preparedness and response to current and future health challenges. Its strategic pillars are:

- **Innovative medical advances:** development of personalized therapies and digital technologies across the pharmaceutical value chain.
- **Sustainable production:** optimization of manufacturing processes to address diseases lacking effective treatments and to enhance environmental sustainability.
- **Industrial and health resilience:** improving preparedness for future health threats while supporting the sector's green transition.

Through its participation in Med4Cure, **Medichem positions itself as a strategic player in the European pharmaceutical ecosystem**, reaffirming its commitment to innovation and sustainability in pharmaceutical technologies, and contributing to the development of a stronger, more autonomous, and resilient European health industry.

About Medichem

Medichem is a B2B pharmaceutical company providing high-quality APIs and FDFs for the generics industry. It offers innovative, sustainable solutions across the pharma value chain. Committed to long-term responsibility, Medichem prioritizes environmental care and continuous improvement.



For more information

info@medichem.es

www.medichem.es

+34 93 477 64 40